Latest news with #HKEX
Yahoo
4 hours ago
- Business
- Yahoo
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO Congress 2025, taking place October 17-21, 2025, in Berlin, Germany. MSS mCRC remains a therapeutic challenge with limited response to immune checkpoint inhibitors. Preclinical evidence supports the synergistic antitumor activity of CTLA-4 blockade combined with PD-(L)1 inhibition in mouse models. In this multicenter, open-label, Phase II study (NCT05167071), heavily pretreated non-liver metastatic MSS mCRC patients were enrolled. Preliminary efficacy and safety data will be presented in a poster session during the ESMO Congress 2025. Details of the poster presentation are as follows: Title: Efficacy and Safety of HBM4003, an anti-CTLA-4 Antibody, Combined with Tislelizumab in MSS Metastatic Colorectal Cancer: A Multicenter, Phase II Study Presentation Number: 807P Speaker: Frank Zheng All accepted abstracts will be published online on the ESMO website. About Porustobart (HBM4003) Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice® platform. It is also the first fully human heavy-chain-only antibody which entered clinical development globally. Compared with conventional CTLA-4 antibodies, porustobart has unique, favorable properties, including significant Treg cell depletion and optimized pharmacokinetics for improved safety. Additionally, by enhancing antibody-dependent cellular cytotoxicity (ADCC), porustobart increases the potential to selectively deplete intratumoral Treg cells, helping to overcome the efficacy and toxicity bottleneck of current CTLA-4 therapies. Harbour BioMed has implemented a global development plan for multiple types of solid tumors with an adaptive treatment design for porustobart. Positive efficacy and safety data have been observed in the monotherapy trials targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC. About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit View original content to download multimedia: SOURCE Harbour BioMed Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
11 hours ago
- Business
- Korea Herald
Ping An Appoints AI Expert Ray Wang as Chief Technology Officer to Accelerate Comprehensive Digital Transformation
HONG KONG and SHANGHAI, July 29, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) has announced the appointment of Mr. Ray Wang as the Group's Chief Technology Officer (CTO) and General Manager of Ping An Technology. The appointment of Ray Wang will significantly enhance the Company's research and development (R&D) and application capabilities in artificial intelligence (AI). His leadership is expected to drive the deep integration of Ping An's self-developed large language models and open-source big data platforms, accelerating the establishment of five key digital systems "digital business, digital operations, digital management, digital marketing, and digital services." This move aims to inject strong momentum into the Company's technology-enabled "integrated finance + health and senior care" dual-driver strategy, further advancing its comprehensive digital transformation. Ray Wang holds a master's degree in computer science from the National University of Singapore. Prior to joining Ping An, he held senior technical management roles at globally renowned companies such as Google and Bloomberg. In 2015, Wang became Chief Architect at Baidu, where he spearheaded the development of Baidu Wallet and financial services. In 2016, he joined Ant Group, serving as Vice President and CTO of Ant Fortune and Ant Insurance. At Ant Group, he led innovations in digital finance and AI, managing technical and research teams across wealth management, insurance, consumer finance, MYbank, and Zhima Credit. He launched pioneering generative AI products such as AI financial assistant and AI financial business assistant. With nearly 20 years of experience in the "finance + technology" sector, Wang brings extensive expertise in the digital transformation of financial services, the development and application of financial large models, top-tier technical skills, and exceptional innovation capabilities. In recent years, Ping An has been oriented by customer needs, focusing on empowering business scenarios as its core strategy. Ping An has continuously invests in R&D to build leading technological capabilities, which have been widely utilized to enable its core financial businesses and accelerate the development of its "integrated finance + health and senior care" ecosystem. This strengthened Ping An's internal smart application of business scenarios, while promoting the digital transformation of the industry as a whole. The Company has built a "953" technology foundation backed by the data of nine major databases, technical support from the five laboratories, and development and application services of the three technology companies, which creating an AI moat. As of the end of 2024, Ping An has a first-class technology team of over 21,000 technology developers and more than 3,000 scientists. As of March 31, 2025, Ping An cumulatively won 45 championships in domestic and overseas AI competitions and cumulatively filed 55,435 patent applications, leading most international financial institutions. About Ping An Group Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-driven "integrated finance + health and senior care" strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its nearly 240 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of December 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 27 th in the Forbes Global 2000 list in 2025 and 47 th in the Fortune Global 500 list in 2025.
Yahoo
15 hours ago
- Automotive
- Yahoo
Li Auto Inc. Launches Li i8, a Six-Seat Battery Electric Family SUV
BEIJING, China, July 29, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. ('Li Auto' or the 'Company') (Nasdaq: LI; HKEX: 2015), a leader in China's new energy vehicle market, today officially launched Li i8, a six-seat battery electric family SUV. As an SUV of the new era, Li i8 combines the all-terrain capabilities of off-road vehicles, the handling dynamics of sedans, and the comfort of MPVs, redefining family mobility with an all-new driving and riding experience. Li i8 offers three trims: Pro, Max and Ultra, which will retail for RMB321,800, RMB349,800 and RMB369,800, respectively. Deliveries of Li i8 will commence on August 20, 2025. Below is an overview of Li i8. For more details, please visit Li Auto's official website. A New High-Voltage BEV Platform Li Auto has developed a new high-voltage battery electric platform for Li i8, featuring an in-house developed electric drive system, 5C battery pack, and a nationwide 5C super charging network. 1) Proprietary Electric Drive System: Ultra-Quiet, Ultra-Efficient Li Auto's in-house developed electric drive system is designed to minimize noise and energy consumption. Its proprietary rotor-stator structure and transmission system can effectively reduce vibration and noise inside the Li i8 cabin, achieving industry-leading cabin quietness. Additionally, Li i8's electric drive system incorporates in-house developed silicon carbide power chips and modules, offering high efficiency, low losses, and rapid heat dissipation for enhanced energy savings. Li Auto also built its own motor factory to ensure the full implementation of in-house technologies. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service The Insurance Savings You Expect Affordable Auto Insurance, Customized for You 2) In-House Developed Ternary Lithium 5C Super Charging Battery Pack Li i8 is equipped with 90.1 kilowatt-hours and 97.8 kilowatt-hours ternary lithium 5C super charging battery pack options. With all-wheel drive offered as standard, Li i8 achieves a CLTC range of 670 kilometers and 720 kilometers for the 90.1 kilowatt-hours and 97.8 kilowatt-hours battery pack options, respectively. The in-house developed drive motor and low-drag design contribute to Li i8's industry-leading range attainment rate. Paired with an industry-leading battery thermal management system, Li i8 ensures sustained high-power charging, achieving a 500-kilometer driving range with just 10 minutes of charging. Furthermore, based on the Company's battery lifespan tests, Li i8's battery health remains above 80% after 1,500 full charge-discharge cycles in super charging mode. 3) The Largest Super Charging Network Among Chinese Automakers To support the rollout of BEVs, Li Auto has built the largest super charging network among Chinese automakers, with 3,000 super charging stations in operation. This network includes approximately 1,000 highway stations covering nine major east–west and nine major north–south highway routes, with an average spacing of about 150 kilometers, along with 2,000 urban stations across over 250 Design Li i8's avant-garde yacht-inspired design achieves low drag, exceptional space utilization, and outstanding visibility. With a drag coefficient of 0.218, the vehicle delivers reduced wind noise and energy consumption. As a large SUV with dimensions of 5,085 millimeters in length, 1,960 millimeters in width, 1,740 millimeters in height, and a 3,050-millimeter wheelbase, its interior space surpasses that of many full-size SUVs. Additionally, Li i8 provides every family user on board with excellent visibility. SUV of a New Era The combined strengths of its outstanding off-road capabilities, handling, and spaciousness position Li i8 as an exceptional SUV for a new era. Li i8 boasts an off-roader's passability, slope-climbing power, and ability to handle rough terrains. In terms of off-road performance, the Li i8 comes standard with a dual-chamber Li Magic Carpet air suspension, offering four adjustable height settings and a maximum ground clearance of 196 millimeters. Additionally, Li i8 is equipped with a dual-motor, all-wheel drive system in the standard configuration across all trims, enabling it to handle a wide range of challenging road conditions. Li i8 delivers sedan-like handling stability, performance, and ease of entry and exit through its battery electric low-center-of-gravity design, a body torsional stiffness of 49,500 Nm/degree, front double-wishbone and rear five-link suspension, a 0-100 km/h acceleration as quick as 4.5 seconds, and a minimum second-row side sill ground clearance of 401 millimeters. Li i8 offers MPV-like premium spaciousness and comfort. Its new wraparound-style seats feature optimized backrest and cushion surfaces, delivering enhanced support and hugging comfort. Li i8 also features a zero-gravity seat on the right side of the second row, a third row comparable to top MPVs, and a trunk depth of 565 millimeters when all three rows are in use, easily meeting the travel needs of large families. Li i8 can also be equipped with a large floating table, delivering an experience rivaling that of the Li MEGA. Industry-Leading Safety Capabilities For passive safety, Li i8 adopts a multi-path force transmission design in the front compartment, featuring three longitudinal force transmission paths to enhance energy dispersion during frontal collisions. The front compartment integrates 11 circular energy-absorbing structures, which effectively absorb and dissipate collision energy, ensuring overall vehicle safety and significantly enhancing the structural integrity of the occupant cabin. Li i8 also features comprehensive airbag protection with extended side curtain airbags and door handles designed to remain unlockable even in power failures. It is also engineered to meet stringent eco-health standards. Additionally, its battery has undergone rigorous safety testing under extreme conditions such as submersion and freezing, complying with rigorous safety protocols. On active safety, all Li i8 trims come standard with LiDAR sensors and are equipped with enhanced automatic emergency steering (AES) to effectively mitigate collision risks from other vehicles. An All-New Assisted Driving and Smart Space Experience In terms of assisted driving, Li i8 Pro comes standard with the Li AD Pro assisted driving system, equipped with a Horizon Robotics J6M chip delivering total computing power of 128 TOPS. The Li i8 Max and Ultra models are equipped with the advanced Li AD Max assisted driving system, featuring an NVIDIA Thor-U chip with a total computing power of 700 TOPS. With the launch of urban NOA on the Horizon Robotics J6M platform by year-end, the assisted driving capabilities of Li AD Pro will be significantly enhanced. The Li AD Max will integrate Li Auto's self-developed VLA driver large model, which possesses understanding, reasoning, memory, and communication capabilities, evolving through reinforcement learning into an increasingly intuitive personal driver. Combining spatial intelligence, linguistic intelligence, and behavioral strategies, the VLA driver large model leverages a human-like technical architecture to deliver notable improvements in safe driving, smoothness and comfort, three-point turns, continuous task execution, and underground parking. The development of the VLA driver large model benefited from Li Auto's R&D advantages in data, algorithms, computing power, and engineering capabilities, including optimized data allocation, the use of generated data, high model evaluation efficiency, a closed loop of reinforcement learning, as well as increasing investments in computing power, robust quantitative accuracy, and multi-platform deployment capabilities. The VLA driver large model will be fully rolled out to AD Max models equipped with Orin-X and Thor-U chips alongside the delivery of Li i8. In terms of smart space, Li Auto's in-house foundation model MindGPT-powered Li Xiang Tong Xue has evolved from a voice assistant to Li Xiang Tong Xue Agent. It can independently utilize tools, resolve complex tasks, and possess personalized memory. Nearly all in-vehicle functions of Li i8 have undergone tool-based integration for Li Xiang Tong Xue Agent, including electric air vents for climate control and windshield wipers. For complex tasks, Li Xiang Tong Xue Agent leverages Li Auto's advanced model capabilities to understand user intent and achieve goals efficiently. For example, it can autonomously invoke tools like the Meituan app to fulfill in-store food pickup requests or activate the vehicle's external cameras to scan QR codes in parking lots for payment. Examples also include the industry-first Desktop Master functionality that enables user-programmable code generation and the creation of tools, content, and services. Furthermore, with the June rollout of Face ID and the new family account system, Li Xiang Tong Xue Agent can remember information about each individual to deliver personalized experiences while ensuring data security—making daily use more convenient, thoughtful and emotionally resonant for every family member. Brand Upgrade At the launch event, Li Auto announced its brand upgrade, committing to providing a high-quality home, a premium private space for a diverse range of consumers while meeting the needs of family users. The Company will uphold its brand value proposition of 'private space, deep connection, and cherished experience,' while continuing to invest in products and intelligence. Through the creation of sophisticated, liberating, and distinctive mobile spaces, Li Auto aims to fulfill its mission: Create a Mobile Home, Create happiness. About Li Auto Inc. Li Auto Inc. is a leader in China's new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家,创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. Its current model lineup includes a high-tech flagship family MPV, four Li L series extended-range electric SUVs, and one Li i series battery electric SUV. The Company will continue to expand its product lineup to target a broader user base. For more information, please visit: Safe Harbor Statement This press release contains statements that may constitute 'forward-looking' statements pursuant to the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to,' 'challenges,' and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC') and The Stock Exchange of Hong Kong Limited (the 'HKEX'), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto's strategies, future business development, and financial condition and results of operations; Li Auto's limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto's ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto's ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto's ability to compete successfully; Li Auto's ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto's vehicles; Li Auto's ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto's filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Li Auto RelationsEmail: ir@ Christensen AdvisoryRoger HuTel: +86-10-5900-1548Email: Li@ Photos accompanying this announcement are available at
Business Wire
2 days ago
- Business
- Business Wire
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA ® in Neoadjuvant/Adjuvant NSCLC Treatment
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA ® (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This recommendation is based on the Phase 3 RATIONALE-315 study (NCT04379635). 'Patients with resectable, early-stage NSCLC face an urgent challenge – despite surgery and current therapies, recurrence rates remain alarmingly high,' said Dr. Mariano Provencio, Head of the Medical Oncology Department at Hospital Universitario Puerta de Hierro and Professor at the Faculty of Medicine of Universidad Autonoma de Madrid in Spain. 'The significant clinical benefit observed in the RATIONALE-315 study has important implications for patients. If approved, perioperative tislelizumab will offer oncologists a powerful new option to improve outcomes and potentially alter the course of this difficult-to-treat disease.' RATIONALE-315 is a double-blind, placebo-controlled, multicenter, Phase 3 study that randomized 453 patients with resectable NSCLC 1:1 to receive either TEVIMBRA plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by TEVIMBRA as adjuvant treatment or placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment. As previously reported at the European Society for Medical Oncology (ESMO) Congress Virtual Plenary in February 2024 1, the dual primary endpoints of event-free survival (EFS) and major pathologic response (MPR) were met at the interim analyses of the RATIONALE-315 study. Results include: Statistically significant and clinically meaningful improvement in MPR and pathological complete response (pCR) rates: 56.2% of NSCLC patients treated with TEVIMBRA in combination with chemotherapy before surgery achieved MPR compared to 15.0% of patients treated with chemotherapy in combination with placebo (difference: 41.1%; 95% CI: 33.2-49.1, p<0.0001) 40.7% of patients on the TEVIMBRA-based regimen achieved pCR, compared to 5.7% of patients treated with chemotherapy in combination with placebo (difference: 35.0%; 95% CI: 27.9-42.1, p<0.0001) Statistically significant EFS (HR [95% CI], 0.56 [0.40–0.79]; 1-sided P=0.0003) and trend for overall survival (OS) (HR [95% CI], 0.62 [0.39–0.98]; 1-sided P=0.0193) benefits favoring TEVIMBRA in early data. Consistent safety profile of the TEVIMBRA arm with that of individual therapies, with 72.1% of patients in the TEVIMBRA arm (vs. 66.4% in the placebo arm) experiencing grade ≥3 treatment-related adverse events (TRAEs) and 15.5% of patients in the TEVIMBRA arm (vs. 8.0% in the placebo arm) experiencing serious TRAEs. There were no new safety signals identified with this regimen, and the most common Grade 3 or 4 TRAEs (≥ 10%) in the TEVIMBRA arm were decreased neutrophil count and decreased white blood cell count. No impact on the feasibility and completeness of surgery, a key concern around neoadjuvant treatment. Updated EFS and OS data from the pre-planned final analysis of RATIONALE-315 will be submitted for presentation at an upcoming medical conference. 'TEVIMBRA is already approved in the EU across multiple settings in NSCLC, the most common form of lung cancer, and this positive CHMP opinion expands its potential to help patients earlier in their treatment journey,' said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. 'As the foundational asset of our solid tumor portfolio, TEVIMBRA continues to demonstrate its strength and versatility across the continuum of care, bringing us closer to our goal of delivering more comprehensive and effective cancer treatment to more patients.' In lung cancer, TEVIMBRA is already approved in the EU for the first-line treatment of patients with squamous NSCLC, for the first-line treatment of patients with non-squamous NSCLC with PD-L1 high expression, for the treatment of patients with locally advanced or metastatic NSCLC after prior platinum-based therapy, and as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). It is also approved as a first-line treatment for patients with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, as a first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC), as a second-line treatment in ESCC after prior platinum-based chemotherapy, and as a first-line treatment for patients with nasopharyngeal carcinoma (NPC). About NSCLC Lung cancer is the most commonly diagnosed type of cancer and the leading cause of cancer-related death worldwide. 2 In Europe, lung cancer is the third most frequent cancer with 484,306 new cases diagnosed in 2022. 3 NSCLC accounts for 80–90% of all lung cancers 4, of which resectable NSCLC patients at diagnosis represent around 25–30% 5. About TEVIMBRA (tislelizumab) TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body's immune cells to detect and fight tumors. TEVIMBRA is the foundational asset of BeOne's solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 35 countries and regions across 70 trials, including 21 registration-enabling studies. TEVIMBRA is approved in 46 countries, and more than 1.5 million patients have been treated globally. Important Safety Information The current European Summary of Product Characteristics (SmPC) for TEVIMBRA is available from the European Medicines Agency. This information is intended for a global audience. Product indications vary by region. About BeOne BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of TEVIMBRA to improve patient outcome and potentially alter the course of the disease and to potentially help patients earlier in their treatment journey; the ability of BeOne to deliver more comprehensive and effective cancer treatment to more patients; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. To access BeOne media resources, please visit our Newsroom site.
Business Upturn
2 days ago
- Business
- Business Upturn
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: . Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
